Morcote, Switzerland

Antonio Francesco Di Naro

This inventor holds 12 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Adienne Pharma & Biotech Sa, Adienne S.a.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Antonio Francesco Di Naro. Retrieved from https://idiyas.com/inventor/antonio-francesco-di-naro

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 1.0

ph-index = 3

Forward Citations = 32(Granted Patents)


Company Filing History:


Years Active: 2016-2026

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: Innovations by Antonio Francesco Di Naro

Introduction

Antonio Francesco Di Naro is a notable inventor based in Morcote, Switzerland. He has made significant contributions to the field of pharmaceuticals, holding a total of 12 patents. His work focuses on innovative methods and products that enhance the preparation and administration of pharmaceutical products.

Latest Patents

One of his latest patents is titled "Multi chamber flexible bag and methods of using same." This invention describes a method for preparing a pharmaceutical product in a single multiple chamber flexible bag. The process involves introducing a pharmaceutical product in a liquid state into a first chamber of the flexible bag through a first port. The product is then lyophilized within the first chamber to create a lyophilized pharmaceutical product. The flexible bag features a second chamber, separated from the first by a breakable seal, which contains a reconstituting solution. Users can apply pressure to the bag to break the seal and mix the contents for administration to patients.

Another significant patent is the "Quantitative cellular method for determining the biological activity of an anti-CD26 ligand." This invention relates to a quantitative cellular method for the in vitro determination of the effect of an anti-CD26 ligand, particularly an anti-CD26 monoclonal antibody, such as begelomab. This method is crucial for evaluating the biological activity of such ligands in pharmaceutical research.

Career Highlights

Throughout his career, Antonio has worked with various companies, including Adienne Pharma & Biotech SA and Adienne SA. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in pharmaceutical technology.

Collaborations

[This section has been skipped due to space constraints.]

Conclusion

Antonio Francesco Di Naro's contributions to the pharmaceutical industry through his innovative patents demonstrate his commitment to improving healthcare solutions. His work continues to influence the development of effective pharmaceutical products.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…